Media completing ignoring issues of rural India, says Sainath

Mangaluru, May 4: The district administration has set up seven check-posts to monitor those entering Dakshina Kannada from other districts and states amidst coronavirus crisis.

The check-posts are located at up seven check-posts at Talapady, Hejamady, Gundya, Jalsoor, Charmadi, Naravi and Kallugundi. 

According to Deputy Commissioner Sindhu B Rupesh, all those who enter the district will be screened. Those who come from outside the district and state will be asked to remain in quarantine. 

As the relaxation is announced for 12 hours, the public should be cautious while venturing out of the house. Wearing a mask in public is mandatory in addition to maintaining social distance. 

Further, she said of the 24 cases reported in the district, only four had symptoms of breathlessness and others were asymptomatic. Of the nine active cases in the district, the condition of one patient is serious while two are likely to be discharged from hospital shortly, said the DC.

Mangaluru, Jul 12: The Expert Committee set up by the District authorities to inquire into death due to Covid-19 in Dakshina Kannada district declared that the death was due to patients late reporting to the hospitals and severe co-morbidities.

''Many were scared to visit the hospitals for treatment. Any patient suffering from fever, cold should stop self-medication and seek the advice of doctors. From what we have observed, the mortality was among patients who reported late to hospitals. Many had ignored symptoms assuming it to be a common cold,'' Expert Committee members Dr Hansraj Alva and Dr Muralidhar Yadiyal told mediapersons on Saturday night.

Wenlock Hospital Superintendent Dr Sadashiv said of the 38 deaths reported in the District, the expert committee had analysed 35 deaths. 9 persons who died are below 50 years old, 10 are in the age group of 50 to 60 years, 11 in the age group of 60 to 70 and five in the age group of above 70 years.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.